pharma · Metastatic Melanoma · Unresectable Melanoma · IOVA
Iovance Biotherapeutics
Iovance Biotherapeutics B.V.
Iovance Biotherapeutics clinical programs — 36 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 825 Industrial Rd, Suite 400, San Carlos, California 94070, US
- Founded
- 2007
- Employees
- 916
- Programs
- 36
- Drugs
- 26
- Patents
- 94
Iovance Biotherapeutics projects
36 ClinicalTrials.gov programs sponsored by Iovance Biotherapeutics.
Iovance Biotherapeutics has 36 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
IOV-MEL-301
Iovance Biotherapeutics B.V.
Melanoma
1 trial -
Lifileucel plus Pembrolizumab
Iovance Biotherapeutics B.V.
Metastatic Melanoma
1 trial -
Aldesleukin
Iovance Biotherapeutics B.V.
Bone Sarcoma
1 trial -
Autologous Tumor Infiltrating Lymphocytes MDA-TIL
Iovance Biotherapeutics B.V.
Malignant Solid Neoplasm
1 trial -
C-145-04
Iovance Biotherapeutics B.V.
Recurrent, metastatic, or persistent Cervical Carcinoma
1 trial -
Cyclophosphamide
Iovance Biotherapeutics B.V.
Clinical Stage IV Cutaneous Melanoma AJCC v8
1 trial -
Cyclophosphamide
Iovance Biotherapeutics B.V.
Metastatic Bladder Urothelial Carcinoma
1 trial -
E7 TCR-T cells
Iovance Biotherapeutics B.V.
HPV-Associated Cervical Carcinoma
1 trial -
E7 TCR-T cells
Iovance Biotherapeutics B.V.
Cervical Cancer
1 trial -
IOV-3001
Iovance Biotherapeutics B.V.
Unresectable Melanoma
1 trial -
IOV-4001
Iovance Biotherapeutics B.V.
Unresectable Melanoma
1 trial -
IOV-COM-202
Iovance Biotherapeutics B.V.
Neoplasm
1 trial -
IOV-LUN-202
Iovance Biotherapeutics B.V.
Metastatic Non-Small-Cell Lung Cancer
1 trial -
IOV-MEL-202
Iovance Biotherapeutics B.V.
Previously treated advanced melanoma
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Metastatic Non Small Cell Lung Cancer
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Cervical Carcinoma
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Cutaneous Squamous Cell Carcinoma
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Squamous Cell Carcinoma of the Head and Neck
1 trial -
LN-145
Iovance Biotherapeutics B.V.
Non Small Cell Lung Cancer
1 trial -
Lifileucel
Iovance Biotherapeutics B.V.
Melanoma (Skin Cancer)
1 trial -
Lifileucel
Iovance Biotherapeutics B.V.
Endometrial Cancer
1 trial -
Lifileucel
Iovance Biotherapeutics B.V.
Metastatic Melanoma
2 trials -
Tumor infiltrating lymphocytes (TIL) LN-145
Iovance Biotherapeutics B.V.
Metastatic Triple Negative Breast Cancer
1 trial -
Cyclophosphamide
Iovance Biotherapeutics B.V.
Locally Advanced Melanoma
1 trial -
IOV-2001
Iovance Biotherapeutics B.V.
Chronic Lymphocytic Leukemia
1 trial -
Interleukin-2
Iovance Biotherapeutics B.V.
Chronic Graft Versus Host Disease
1 trial -
KK-LC-1 TCR-T cells
Iovance Biotherapeutics B.V.
Gastric Cancer
1 trial -
LN-144
Iovance Biotherapeutics B.V.
Stage IIIB Melanoma
1 trial -
LN-145/LN-144
Iovance Biotherapeutics B.V.
Soft Tissue Sarcoma
1 trial -
Lifileucel (LN-144)
Iovance Biotherapeutics B.V.
Metastatic Melanoma
1 trial -
Lifileucel (LN-144/LN-145)
Iovance Biotherapeutics B.V.
Uveal Melanoma
1 trial -
Nivolumab
Iovance Biotherapeutics B.V.
Melanoma (Skin)
1 trial -
Nivolumab
Iovance Biotherapeutics B.V.
Non-Small Cell Lung Cancer
1 trial -
TIL
Iovance Biotherapeutics B.V.
Sarcoma
1 trial -
locally manufactured adoptive cellular therapy (ACT) product
Iovance Biotherapeutics B.V.
Malignant Pleural Effusion
1 trial -
Ipilimumab
Iovance Biotherapeutics B.V.
Metastatic Melanoma
1 trial
Frequently asked questions
How many clinical projects does Iovance Biotherapeutics have?
36 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.